Cargando…

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings

BACKGROUND: Dalbavancin is a lipoglycopeptide antibiotic active against Gram-positive organisms with an extended half-life that allows for weekly dosing. Initially approved for treating skin and soft-tissue infections, use for more complicated infections provides several potential benefits, particul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Streifel, Amber C, Sikka, Monica, Lewis, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811143/ http://dx.doi.org/10.1093/ofid/ofz360.892

Ejemplares similares

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs
por: Douglass, Alyse H., et al.
Publicado: (2023)

597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy
por: Nakrani, Monark, et al.
Publicado: (2020)

188. Outcomes After Implementing the OPTIONS-DC Multidisciplinary Care Conference for Patients with Substance Use Disorders and Severe Bacterial Infections
por: Schneider, Brenton J, et al.
Publicado: (2021)

1801. About Damn Time: HAV, HBV, and Tetanus Screening and Vaccination during Hospitalization in Persons who Use Drugs
por: Streifel, Amber C, et al.
Publicado: (2023)

The challenge of antibiotic selection in prosthetic joint infections due to Corynebacterium striatum: a case report
por: Streifel, Amber C., et al.
Publicado: (2022)

Screening for co-infections in patients with substance use disorders and severe bacterial infections
por: Varley, Cara D., et al.
Publicado: (2022)

Description and outcomes of patients with substance use disorder with serious bacterial infections who had a multidisciplinary care conference
por: Conte, Michael, et al.
Publicado: (2022)

1762. A Review of Antibiotic Outcomes Data Utilizing the Multidisciplinary OPTIONS-DC Conference for PWUD
por: Douglass, Alyse H, et al.
Publicado: (2022)

788. Outcomes of Multidisciplinary Care Conferences for Patients with Substance Use Disorders Requiring Prolonged Antimicrobial Therapy for Severe Infections
por: Gore, Sara J, et al.
Publicado: (2019)

Transition of Care with Dalbavancin: a Successful Cost-Saving Stewardship Program through Decreased Length of Stay
por: Terriff, Colleen
Publicado: (2017)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

742. The Development, Implementation, and Feasibility of Multidisciplinary Treatment Planning Conference for Individuals with Unstable Substance Use Disorders and Active Infections Requiring Prolonged Antimicrobial Therapy: The OPTIONS-DC Model
por: Strnad, Luke, et al.
Publicado: (2019)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Lueking, Richard, et al.
Publicado: (2022)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

1028. Performance and Patient Acceptability Evaluation of the Chembio DPP® HIV-Syphilis Assay in an Emergency Department
por: Maliszewski, Kendall N, et al.
Publicado: (2021)

Improved hospital discharge and cost savings with esophageal cooling during left atrial ablation
por: Joseph, Christopher, et al.
Publicado: (2023)

1351. Use of Mail-Out Sexually Transmitted Infection Test Kits in a Telehealth Pre-exposure Prophylaxis Clinic
por: Sikka, Monica K, et al.
Publicado: (2021)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

2765. Dalbavancin for challenging left ventricular assist device driveline infections
por: Doligalski, Christina, et al.
Publicado: (2023)

Association of Human Papilloma Virus 16 Infection and p53 Polymorphism among Tobacco using Oral Leukoplakia Patients: A Clinicopathologic and Genotypic Study
por: Sikka, Seema, et al.
Publicado: (2014)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

1730. Real-World Use Of Dalbavancin In A US Tertiary Referral Center
por: Bhugra, Mudita, et al.
Publicado: (2022)

Investigation of Mycobacterium Pseudo-outbreak
por: Elsheikh, Malak, et al.
Publicado: (2017)

1286. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
por: Shaw, Michael, et al.
Publicado: (2023)

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
por: Greckel, Meagan N, et al.
Publicado: (2022)

1028. Synergizing Infectious Diseases and Substance Use Treatment to Improve the Outcomes of Endocarditis in People Who Inject Drugs at a Large Academic Hospital
por: Meisner, Jessica, et al.
Publicado: (2018)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

744. Infectious Diseases Providers Perspectives Around the Use of Outpatient Parenteral Antibiotic Therapy (OPAT) for Persons Who Inject Drugs (PWID), US, 2022
por: Solomon, Daniel A, et al.
Publicado: (2022)

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ni8af5jhjs82l3qm8k9adk5fh1